Damian Rigatti, DO
Family Medicine · Neshanic Station, NJNPI 1154311579
Payments from drug & device makers
Across 552 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- GSK$696
- Lilly USA, LLC$630
- Bayer$451
- plus $4K from 31 others
What the payments were for
- Food & beverage$11,149100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $2,056 |
| AstraZeneca | 78 | $1,794 |
| Novo Nordisk | 104 | $1,640 |
| GSK | 26 | $696 |
| Lilly USA, LLC | 37 | $630 |
| Bayer | 13 | $451 |
| Boehringer Ingelheim | 23 | $433 |
| Merck | 21 | $404 |
| Amarin Pharma, Inc. | 16 | $390 |
| Johnson & Johnson | 15 | $319 |
| Optinose US, Inc. | 4 | $266 |
| Pfizer | 17 | $251 |
| Teva Pharmaceuticals USA, Inc. | 2 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $192 |
| Amgen | 9 | $134 |
| Otsuka America Pharmaceutical, Inc. | 8 | $129 |
| Axsome Therapeutics, Inc. | 7 | $127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $115 |
| Exact Sciences | 6 | $115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $115 |
| Abbott | 7 | $108 |
| Eisai Inc. | 5 | $75 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Bausch Health US, LLC | 4 | $61 |
| Arbor Pharmaceuticals, Inc. | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 4 | $49 |
| Novartis | 3 | $44 |
| Medtronic | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Corcept Therapeutics | 1 | $19 |
| Seqirus USA Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$350
- Kerendia$250
- NUCALA$250
- Xhance$243
- AIRSUPRA$241
- ArmonAir Digihaler$238
- ProAir Digihaler$238
- AirDuo RespiClick$238
- QULIPTA$226
- UBRELVY$214
- CAPVAXIVE$125
- Vascepa$122
- XARELTO$116
- DUPIXENT$115
- TRELEGY ELLIPTA$112
- Wegovy$104
- Saxenda$104
- MOUNJARO$103
How this compares
$11,154 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 51 | $68,457 |
| OzempicSemaglutide | 46 | $58,381 |
| MounjaroTirzepatide | 31 | $50,463 |
| FarxigaDapagliflozin Propanediol | 38 | $32,373 |
| RybelsusSemaglutide | 18 | $24,358 |
| EliquisApixaban | 17 | $22,472 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $19,334 |
| TradjentaLinagliptin | 12 | $12,552 |
| VascepaIcosapent Ethyl | 12 | $11,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,169 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,461 |
| Testosterone | 12 | $5,091 |
| SynthroidLevothyroxine Sodium | 45 | $4,478 |
| Atorvastatin Calcium | 362 | $3,605 |
| Perindopril Erbumine | 42 | $2,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,640 | $82,73864 claims |
| Boehringer IngelheimJardiance, Tradjenta | $433 | $81,00963 claims |
| Lilly USA, LLCMounjaro | $630 | $50,46331 claims |
| AstraZenecaFarxiga | $1,794 | $32,37338 claims |
| PfizerEliquis | $251 | $22,47217 claims |
| MerckJanumet | $404 | $19,33418 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $696 | $16,63029 claims |
| AbbVieSynthroid | $2,056 | $4,47845 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Neshanic Station
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.